Cargando…
Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach
By September 1, 2021, SARS-CoV-2, a respiratory virus that prompted Coronavirus Disease in 2019, had infected approximately 218,567,442 patients and claimed 4,534,151 lives. There are currently no specific treatments available for this lethal virus, although several drugs, including remdesivir and h...
Autores principales: | Shahabadi, Nahid, Zendehcheshm, Saba, Mahdavi, Mohammad, Khademi, Fatemeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455240/ https://www.ncbi.nlm.nih.gov/pubmed/34568544 http://dx.doi.org/10.1016/j.imu.2021.100745 |
Ejemplares similares
-
Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective
por: Shahabadi, Nahid, et al.
Publicado: (2023) -
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
por: Yuan, Shuofeng, et al.
Publicado: (2020) -
Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches
por: Shahabadi, Nahid, et al.
Publicado: (2022) -
Selenium nanoparticles: Synthesis, in-vitro cytotoxicity, antioxidant activity and interaction studies with ct-DNA and HSA, HHb and Cyt c serum proteins
por: Shahabadi, Nahid, et al.
Publicado: (2021) -
Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children
por: Chera, Alexandra, et al.
Publicado: (2022)